Gain Therapeutics received FDA clearance for its Investigational New Drug (IND) application for GT-02287, enabling the start of Phase 2 clinical trials for Parkinson’s disease in the U.S. during the third quarter of 2026. GT-02287 showed promising Phase 1 results with evidence of target engagement, safety, and improvements in symptoms such as smell, gait, and sleep. The drug, developed using Gain’s AI platform, aims to modify disease progression rather than just relieve symptoms. The Phase 2a study will enroll participants in the U.S., Australia, and Europe to further evaluate efficacy and safety.
DBV Technologies is preparing to submit a Biologics License Application (BLA) for its VIASKIN® Peanut patch aimed at children aged 4 to 7 years. The company has engaged in detailed discussions with the FDA to ensure a thorough and efficient review pr...
Bron, a self-custody crypto wallet provider, has partnered with Noah, a global stablecoin payments infrastructure company, to enable seamless on- and off-ramp access for stablecoins. This integration allows Bron users to easily fund and withdraw from...
Gold and silver prices fell after the North American cash-market close, pressured by rising oil prices and stronger U.S. Treasury yields that heightened concerns over Federal Reserve interest rate hikes. Despite renewed U.S.-Iran tensions causing som...
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Futu Holdings Limited, alleging the company violated China Securities Regulatory Commission rules by operating without proper licenses. The lawsuit claims Futu's financial results w...
AeroVironment reported strong Q4 results with earnings of $1.84 per share beating the $1.46 estimate and revenue doubling to $642 million, surpassing the $559 million forecast. The company's funded backlog rose to $1.2 billion, up 65% from last year,...
